PLGA/Nano-ZnO Composite Particles for Use in Biomedical Applications: Preparation, Characterization, and Antimicrobial Activity

Figure 7

Minimal inhibitory concentrations of ZnO and PLGA/nano-ZnO nanoparticles determined using a broth microdilution assay against Gram-positive bacteria Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), and Bacillus subtilis (ATCC 6633) and the Gram-negative bacteria Klebsiella pneumoniae (ATCC 13883), Escherichia coli (ATCC 25922), Salmonella abony (NTCT – 6017) and Pseudomonas aeruginosa (ATCC 27853), and the yeast Candida albicans (ATCC 24433).